Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPD Consolidation in NDMM
NCT06879379Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Molecular Glues
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib and pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Minimal Residual Disease Negativity Rate at 36 months and Overall Response Rate at 36 months. Started Mar 2025; status: recruiting.
02
Drugs
carfilzomibpomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06879379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879379.